Pharmaceutical

Biogen and Neomorph enter molecular glue degrader deal

Biogen and Neomorph have partnered to discover and develop molecular glue degraders for treating Alzheimer’s and other rare conditions.

Nov 1, 2024 - 04:00
Biogen and Neomorph enter molecular glue degrader deal
Biogen and Neomorph have partnered to discover and develop molecular glue degraders for treating Alzheimer’s and other rare conditions.
Read the original article

Tags:

Previous Article

Bladder cancer diagnoses to top 300,000 in major markets by 2033

Next Article

Will the tide turn for the wave of pharma layoffs?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Listen: ChatGPT in medicine, a boom in weight loss pills, & Sarepta at the FDA

Listen: ChatGPT in medicine, a boom in weight loss pill...

May 25, 2023

STAT+: FDA proposes changes to key approval pathway for medical devices, five years after promising

STAT+: FDA proposes changes to key approval pathway for...

Sep 12, 2023

Genespire raises $52m in Series B to trial paediatric gene therapy

Genespire raises $52m in Series B to trial paediatric g...

Sep 26, 2024